AstraZeneca Atacand HCT
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA clears combination of the angiotensin-2 receptor antagonist candesartan and the diuretic hydrochlorothiazide Sept. 5 for second-line treatment of hypertension. Candesartan is marketed without hydrochlorothiazide as Atacand